Publication

Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies

van den Munckhof, I. C. L., Kurilshikov, A., ter Horst, R., Riksen, N. P., Joosten, L. A. B., Zhernakova, A., Fu, J., Keating, S. T., Netea, M. G., de Graaf, J. & Rutten, J. H. W., Dec-2018, In : Obesity Reviews. 19, 12, p. 1719-1734 16 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van den Munckhof, I. C. L., Kurilshikov, A., ter Horst, R., Riksen, N. P., Joosten, L. A. B., Zhernakova, A., Fu, J., Keating, S. T., Netea, M. G., de Graaf, J., & Rutten, J. H. W. (2018). Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies. Obesity Reviews, 19(12), 1719-1734. https://doi.org/10.1111/obr.12750

Author

van den Munckhof, I. C. L. ; Kurilshikov, A. ; ter Horst, R. ; Riksen, N. P. ; Joosten, L. A. B. ; Zhernakova, A. ; Fu, J. ; Keating, S. T. ; Netea, M. G. ; de Graaf, J. ; Rutten, J. H. W. / Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease : a systematic review of human studies. In: Obesity Reviews. 2018 ; Vol. 19, No. 12. pp. 1719-1734.

Harvard

van den Munckhof, ICL, Kurilshikov, A, ter Horst, R, Riksen, NP, Joosten, LAB, Zhernakova, A, Fu, J, Keating, ST, Netea, MG, de Graaf, J & Rutten, JHW 2018, 'Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies', Obesity Reviews, vol. 19, no. 12, pp. 1719-1734. https://doi.org/10.1111/obr.12750

Standard

Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease : a systematic review of human studies. / van den Munckhof, I. C. L.; Kurilshikov, A.; ter Horst, R.; Riksen, N. P.; Joosten, L. A. B.; Zhernakova, A.; Fu, J.; Keating, S. T.; Netea, M. G.; de Graaf, J.; Rutten, J. H. W.

In: Obesity Reviews, Vol. 19, No. 12, 12.2018, p. 1719-1734.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van den Munckhof ICL, Kurilshikov A, ter Horst R, Riksen NP, Joosten LAB, Zhernakova A et al. Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies. Obesity Reviews. 2018 Dec;19(12):1719-1734. https://doi.org/10.1111/obr.12750


BibTeX

@article{a648504843804583830da9e6073582d5,
title = "Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies",
abstract = "A hallmark of obesity is chronic low-grade inflammation, which plays a major role in the process of atherosclerotic cardiovascular disease (ACVD). Gut microbiota is one of the factors influencing systemic immune responses, and profound changes have been found in its composition and metabolic function in individuals with obesity. This systematic review assesses the association between the gut microbiota and markers of low-grade inflammation in humans. We identified 14 studies which were mostly observational and relatively small (n = 10 to 471). The way in which the microbiome is analysed differed extensively between these studies. Lower gut microbial diversity was associated with higher white blood cell counts and high sensitivity C-reactive protein (hsCRP) levels. The abundance of Bifidobacterium, Faecalibacterium, Ruminococcus and Prevotella were inversely related to different markers of low-grade inflammation such as hsCRP and interleukin (IL)-6. In addition, this review speculates on possible mechanisms through which the gut microbiota can affect low-grade inflammation and thereby ACVD. We discuss the associations between the microbiome and the inflammasome, the innate immune system, bile acids, gut permeability, the endocannabinoid system and TMAO. These data reinforce the importance of human research into the gut microbiota as potential diagnostic and therapeutic strategy to prevent ACVD.",
keywords = "Atherosclerotic cardiovascular disease, gut microbiome, inflammation, obesity, HIGH-FAT-DIET, TRIMETHYLAMINE-N-OXIDE, METABOLIC-DISORDERS, INSULIN-RESISTANCE, IMMUNE-SYSTEM, INTESTINAL MICROBIOTA, CAROTID ATHEROSCLEROSIS, COLONIC INFLAMMATION, INDUCED OBESITY, ENDOTOXEMIA",
author = "{van den Munckhof}, {I. C. L.} and A. Kurilshikov and {ter Horst}, R. and Riksen, {N. P.} and Joosten, {L. A. B.} and A. Zhernakova and J. Fu and Keating, {S. T.} and Netea, {M. G.} and {de Graaf}, J. and Rutten, {J. H. W.}",
year = "2018",
month = dec,
doi = "10.1111/obr.12750",
language = "English",
volume = "19",
pages = "1719--1734",
journal = "Obesity Reviews",
issn = "1467-7881",
publisher = "Wiley",
number = "12",

}

RIS

TY - JOUR

T1 - Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease

T2 - a systematic review of human studies

AU - van den Munckhof, I. C. L.

AU - Kurilshikov, A.

AU - ter Horst, R.

AU - Riksen, N. P.

AU - Joosten, L. A. B.

AU - Zhernakova, A.

AU - Fu, J.

AU - Keating, S. T.

AU - Netea, M. G.

AU - de Graaf, J.

AU - Rutten, J. H. W.

PY - 2018/12

Y1 - 2018/12

N2 - A hallmark of obesity is chronic low-grade inflammation, which plays a major role in the process of atherosclerotic cardiovascular disease (ACVD). Gut microbiota is one of the factors influencing systemic immune responses, and profound changes have been found in its composition and metabolic function in individuals with obesity. This systematic review assesses the association between the gut microbiota and markers of low-grade inflammation in humans. We identified 14 studies which were mostly observational and relatively small (n = 10 to 471). The way in which the microbiome is analysed differed extensively between these studies. Lower gut microbial diversity was associated with higher white blood cell counts and high sensitivity C-reactive protein (hsCRP) levels. The abundance of Bifidobacterium, Faecalibacterium, Ruminococcus and Prevotella were inversely related to different markers of low-grade inflammation such as hsCRP and interleukin (IL)-6. In addition, this review speculates on possible mechanisms through which the gut microbiota can affect low-grade inflammation and thereby ACVD. We discuss the associations between the microbiome and the inflammasome, the innate immune system, bile acids, gut permeability, the endocannabinoid system and TMAO. These data reinforce the importance of human research into the gut microbiota as potential diagnostic and therapeutic strategy to prevent ACVD.

AB - A hallmark of obesity is chronic low-grade inflammation, which plays a major role in the process of atherosclerotic cardiovascular disease (ACVD). Gut microbiota is one of the factors influencing systemic immune responses, and profound changes have been found in its composition and metabolic function in individuals with obesity. This systematic review assesses the association between the gut microbiota and markers of low-grade inflammation in humans. We identified 14 studies which were mostly observational and relatively small (n = 10 to 471). The way in which the microbiome is analysed differed extensively between these studies. Lower gut microbial diversity was associated with higher white blood cell counts and high sensitivity C-reactive protein (hsCRP) levels. The abundance of Bifidobacterium, Faecalibacterium, Ruminococcus and Prevotella were inversely related to different markers of low-grade inflammation such as hsCRP and interleukin (IL)-6. In addition, this review speculates on possible mechanisms through which the gut microbiota can affect low-grade inflammation and thereby ACVD. We discuss the associations between the microbiome and the inflammasome, the innate immune system, bile acids, gut permeability, the endocannabinoid system and TMAO. These data reinforce the importance of human research into the gut microbiota as potential diagnostic and therapeutic strategy to prevent ACVD.

KW - Atherosclerotic cardiovascular disease

KW - gut microbiome

KW - inflammation

KW - obesity

KW - HIGH-FAT-DIET

KW - TRIMETHYLAMINE-N-OXIDE

KW - METABOLIC-DISORDERS

KW - INSULIN-RESISTANCE

KW - IMMUNE-SYSTEM

KW - INTESTINAL MICROBIOTA

KW - CAROTID ATHEROSCLEROSIS

KW - COLONIC INFLAMMATION

KW - INDUCED OBESITY

KW - ENDOTOXEMIA

U2 - 10.1111/obr.12750

DO - 10.1111/obr.12750

M3 - Article

VL - 19

SP - 1719

EP - 1734

JO - Obesity Reviews

JF - Obesity Reviews

SN - 1467-7881

IS - 12

ER -

ID: 71298152